Successful Management of Polysubstance Dependence Syndrome with Endoxifen – A Case Report

Downloads

Published

2025-06-30

Dimensions Badge

Issue

Vol. 5 No. 01 (2025): Indian Journal of Clinical Psychiatry

Section

CASE STUDY

License

Copyright (c) 2025 Jasdeep Saluja

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors

  • Jasdeep Saluja MBBS, Bharati Vidyapeeth University, Pune, Maharashtra, India.

Abstract

This is a case report of a 32-year-old male, a known case of polysubstance dependence syndrome, including cannabis, alcohol, nicotine, and cocaine, with a history of multiple relapses. He was admitted to a psychiatric facility multiple times for detoxification and psychotherapy. After being treated with endoxifen, the patient was able to maintain abstinence from substances for 18 months. This case highlights the successful Management of polysubstance dependence syndrome with endoxifen.

 

How to Cite

Saluja, J. (2025). Successful Management of Polysubstance Dependence Syndrome with Endoxifen – A Case Report. Indian Journal of Clinical Psychiatry, 5(01), 45–47. Retrieved from https://www.ijocp.com/index.php/IJOCP/article/view/163

Downloads

Download data is not yet available.

References

Mclellan AT. Substance Misuse and Substance use Disorders: Why do they Matter in Healthcare? Trans Am Clin Climatol Assoc. 2017;128:112–30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525418/

Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders. JAMA Netw Open. 2020 Jun 19;3(6):e208279. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305524/

Lee AM, Messing RO. Protein kinases and addiction. Ann N Y Acad Sci. 2008 Oct;1141:22-57. https://pmc.ncbi.nlm.nih.gov/articles/PMC3050040/

Battaini F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol Res. 2001 Nov;44(5):353–61. https://pubmed.ncbi.nlm.nih.gov/11712865/

Singh N, Nandy SK, Jyoti A, Saxena J, Sharma A, Siddiqui AJ, Sharma L. Protein Kinase C (PKC) in Neurological Health: Implications for Alzheimer's Disease and Chronic Alcohol Consumption. Brain Sci. 2024 May 29;14(6):554. https://pubmed.ncbi.nlm.nih.gov/38928554/

Dubey V. Long‐term effectiveness and safety of endoxifen in the treatment of bipolar mania: A case report. Int J Adv Med. 2022;9(2):169–172. https://www.ijmedicine.com/index.php/ijam/article/view/3311

Thanvi V. Real‐world long‐term experience on endoxifen in bipolar disorder with psychotic symptoms. Case Rep Psychiatry. 2022;2022:3684181. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271003/

Tharoor H. End of craving with endoxifen in substance use & bipolar disorder. J Clin Pharmacol Ther. 2023;4(3):1048. https://www.medtextpublications.com/open-access/end-of-craving-with-endoxifen-in-substance-use-amp-bipolar-1498.pdf

Ahmad A, Sheikh S, Khan MA, Chaturvedi A, Patel P, Patel R, et al. Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 2021 Sep;23(6):595-603. https://pubmed.ncbi.nlm.nih.gov/33368969/